Publications Repository - Helmholtz-Zentrum Dresden-Rossendorf
|Total number to be selected: 1 Title record|
Development of PSMA-1007 - Related Series of 18F-Labeled Glu-ureido type PSMA inhibitors.
Cardinale, J.; Roscher, M.; Schaefer, M.; Geerlings, M.; Benešová, M.; Bauder-Wüst, U.; Remde, Y.; Eder, M.; Novakova, Z.; Motlová, L.; Bařinka, C.; Giesel, F.; Kopka, K.
In recent years, a number of drugs targeting the prostate specific-membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker-structure, insight into the structure-activity relationship could be gained highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA-protein and analyzed by X-ray with mixed results. Amongst these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [18F]PSMA-1007 was translated into the clinic and is in the meantime subject of advanced clinical trials.
Keywords: PET Tracer; PSMA ligands; prostate cancer; PSMA-1007; PSMA inhibitors
Journal of Medicinal Chemistry (2020)
Online First (2020) DOI: 10.1021/acs.jmedchem.9b01479